U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

Submitted by admin on March 14, 2019 - 10:18am
Source: 
Yahoo/Reuters
News Tags: 
Celgene
Revlimid
patents
Multiple Myeloma
Alvogen
Headline: 
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
snippet: 

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

Do Not Allow Advertisers to Use My Personal information